Steadyfutal 24 mg 40 tablets
Future Pharma
Future Pharma
Composition
• Active ingredient: Betahistine dihydrochloride — 24 mg
Pharmacological properties
• Improves microcirculation in the inner ear
• Increases blood flow in the basilar artery
• Reduces the frequency and intensity of dizziness attacks
• Reduces the sensation of tinnitus and hearing loss
• Acts as an H1 receptor agonist and H3 receptor antagonist
Indications for use
• Meniere's disease
• Symptomatic treatment of vestibular vertigo
• Tinnitus
• Hearing loss associated with impaired vestibular function
Method of administration and dosage
• The dosage of Betahistine varies depending on the age and health condition of the patient, but the dosage for adults is usually as follows:
o Initial dose: At the beginning of treatment, the doctor prescribes 8-16 mg 3 times a day.
o Maintenance dose: the doctor adjusts the dose depending on the patient's condition and response to treatment. The dose is 24-28 mg, divided into 3 doses.
o Maximum dose: 48 mg per day.
• The effect may occur after several days or weeks of regular use
• The course of treatment is selected individually, often long-term.